<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70342">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702441</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-9778-CI-2002</org_study_id>
    <nct_id>NCT01702441</nct_id>
  </id_info>
  <brief_title>Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema</brief_title>
  <official_title>Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerpio Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerpio Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
      pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous
      injections daily for 28 days in patients with diabetic macular edema (DME).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs).</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in physical exams.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in electrocardiograms (ECGs).</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in opthalmic exams.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory assay results.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood chemistry, hematology and urinalysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AKB-9778</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximum plasma drug concentration (Cmax). Area under the plasma concentration-time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in optical tomography (OCT)-measured retinal thickness.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in best corrected visual acuity (BCVA).</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetic Macular Edema (DME)</condition>
  <arm_group>
    <arm_group_label>AKB-9778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous AKB-9778</intervention_name>
    <arm_group_label>AKB-9778</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The following is an abbreviated list of inclusion criteria:

          -  Adults between 18 to 80 years of age, inclusive

          -  Diagnosis of diabetes mellitus (type 1 or type 2)

          -  Decrease in vision determined to be primarily the result of DME in the study eye

          -  Definite Retinal thickening due to diffuse DME involving the center of the macula in
             the study eye

          -  Mean central subfield thickness of at least 325 µm by OCT in the study eye

          -  Early Treatment Diabetic Retinopathy Study (ETDRS) letter score BCVA ≤ 70 (20/40) in
             the study eye

        Exclusion Criteria:

        The following is an abbreviated list of exclusion criteria:

          -  Hemoglobin A1C (HbA1C) ≥ 11.5%

          -  History of any of the following in the study eye (however, the following are not
             exclusionary in the fellow eye):

               1. Panretinal scatter photocoagulation (PRP) or focal laser within 12 weeks prior
                  to Screening

               2. Prior pars plana vitrectomy within 12 weeks prior to Screening

               3. Any ocular surgery within 12 weeks prior to Screening

               4. YAG capsulotomy within 7 days prior to Screening

               5. Prior intravitreal, subtenon, or periocular steroid therapy within 3 months
                  prior to Screening or prior treatment with intravitreal anti-VEGF treatment
                  within 1 month of Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Peters, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aerpio Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
